Clinical Trials | December 22, 2025
Ipsen’s FALKON trial falls short in rare FOP study, offers key insights
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
India plays a critical role in Bristol Myers Squibb’s global strategy
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
Subscribe To Our Newsletter & Stay Updated
